This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Lorus Therapeutics Announces Presentation Of Biomarker Data For LOR-253 At 2013 AACR Annual Meeting

Stocks in this article: LOR

TORONTO, April 10, 2013 (GLOBE NEWSWIRE) -- Lorus Therapeutics Inc. (TSX:LOR) ("Lorus"), a biopharmaceutical company specializing in the discovery, research and development of pharmaceutical products and technologies for the management of cancer, today announced the presentation of novel biomarker data for its lead cancer therapy LOR-253 at the 2013 Annual Meeting of the American Association for Cancer Research (AACR), held in Washington, DC from April 6 – 10, 2013.

The poster presentation titled "Utilization of KLF4 as a pharmacodynamic biomarker for in vivo anticancer activity of a novel small molecule drug LOR-253" will be presented today in the Biomarkers of Drug Response session of the meeting. The abstract for the presentation (Abstract Number: 4649) is available online on the AACR website ( The poster will be available on the Lorus website following the presentation ( ).

The presentation covers data from preclinical studies on anticancer activity and tumor biomarker analysis for LOR-253 in animal models of human non-small cell lung cancer (NSCLC). The studies show that LOR-253 has a significant antitumor activity with a dose-response effect in NSCLC that is associated with a dose dependent increase of the tumor suppressor Krüppel-like Factor 4 (KLF4). When tumors are analyzed at different time points following treatment with the same dosing schedule being used in the LOR-253 clinical study, KLF4 protein is significantly increased after eight doses of LOR-253, which corresponds to two treatment cycles in the clinical study.

"These data represent an important part of our biomarker strategy for LOR-253, which we believe will translate into the clinic when we examine KLF4 expression in tumor biopsies from patients in the biomarker study," said Dr. Aiping Young, Lorus' President and CEO. "Biomarkers for LOR-253 will be valuable for the interpretation of our clinical data and for optimization of dosing in patients. The findings provide strong evidence to support the use of KLF4 as a biomarker for LOR-253 anticancer activity, and we look forward to sharing these exciting results with the cancer research community at the AACR." 

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs